Loading...
XNASNRXP
Market cap4mUSD
Jan 10, Last price  
4.85USD
1D
28.99%
1Q
254.01%
IPO
-94.95%
Name

NRX Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:NRXP chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
53.38%
Rev. gr., 5y
%
Revenues
0k
Net income
-30m
L-14.43%
-105,03366,101408,427-12,347,000-71,715,000-35,235,000-30,150,000
CFO
-22m
L-45.52%
-135,807-473,187-792,731-2,265,000-37,703,000-39,755,000-21,657,000
Earnings
Mar 26, 2025

Profile

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
URL
https://www.nrxpharma.com/
IPO date
Nov 20, 2017
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
27,587
44,401
Unusual Expense (Income)
NOPBT
(27,587)
(44,401)
NOPBT Margin
Operating Taxes
(9)
(4,581)
Tax Rate
NOPAT
(27,578)
(39,820)
Net income
(30,150)
-14.43%
(35,235)
-50.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
8,122
22,702
BB yield
-233.05%
-31.10%
Debt
Debt current
9,161
8,703
Long-term debt
1,822
Deferred revenue
Other long-term liabilities
Net debt
4,566
(9,529)
Cash flow
Cash from operating activities
(21,657)
(39,755)
CAPEX
(3)
(10)
Cash from investing activities
(3)
(10)
Cash from financing activities
6,201
32,214
FCF
(24,575)
(39,820)
Balance
Cash
4,595
20,054
Long term investments
Excess cash
4,595
20,054
Stockholders' equity
(253,063)
(222,992)
Invested Capital
250,491
240,926
ROIC
ROCE
1,072.59%
EV
Common stock shares outstanding
7,576
65,767
Price
0.46
-58.56%
1.11
-76.78%
Market cap
3,485
-95.23%
73,001
-67.45%
EV
8,054
63,472
EBITDA
(27,582)
(44,397)
EV/EBITDA
Interest
120
4,581
Interest/NOPBT